SAREPTA THERAPEUTICS, INC. Lessee, Operating Lease, Liability, to be Paid
SAREPTA THERAPEUTICS, INC. (SRPT) had Lessee, Operating Lease, Liability, to be Paid of $340.31 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue · last filed 2026-03-02
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid $340.31M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid $382.27M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid $398.64M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid $101.70M.
| Period end | Lessee, Operating Lease, Liability, to be Paid |
|---|---|
| 2025-12-31 | $340.31M 10-K · filed 2026-03-02 |
| 2024-12-31 | $382.27M 10-K · filed 2025-02-28 |
| 2023-12-31 | $398.64M 10-K · filed 2024-02-28 |
| 2022-12-31 | $101.70M 10-K · filed 2023-02-28 |
| 2021-12-31 | $64.23M 10-K · filed 2022-03-01 |
| 2020-12-31 | $119.44M 10-K · filed 2021-03-01 |
| 2019-12-31 | $68.04M 10-K · filed 2020-02-26 |
| 2019-09-30 | $70.85M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $71.52M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $74.11M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |